Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07195175

Study of MAR002 in Healthy Men

First in Human, Randomized, Blinded, Placebo-Controlled Single Ascending Dose and Multiple Dose Study of MAR002 in Healthy Men

Status
Recruiting
Phase
Phase 1
Study type
Interventional
Enrollment
45 (estimated)
Sponsor
Marea Therapeutics · Industry
Sex
Male
Age
18 Years – 40 Years
Healthy volunteers
Accepted

Summary

Evaluate the safety and tolerability of subcutaneous (SC) administration of MAR002 in healthy men

Conditions

Interventions

TypeNameDescription
DRUGMAR002subcutaneous injection
DRUGPlaceboSubcutaneous injection

Timeline

Start date
2025-08-11
Primary completion
2026-07-01
Completion
2026-07-01
First posted
2025-09-26
Last updated
2026-01-12

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT07195175. Inclusion in this directory is not an endorsement.